Vividion Therapeutics Overview

  • Founded
  • 2013
Founded
  • Status
  • IPO Registration
  • Employees
  • 107
Employees
  • Latest Deal Type
  • IPO
  • (Announced)
  • Latest Deal Amount
  • $100M
Latest Deal Amount
  • Investors
  • 23

Vividion Therapeutics General Information

Description

Developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses. The company's platform applies chemical proteomics to expand the druggable proteome and addresses difficult targets providing transformative treatments, enabling healthcare professionals to eliminate artifacts and create proteome-wide drug interaction maps, for simultaneous target engagement and global selectivity profiling.

Contact Information

Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 5820 Nancy Ridge Drive
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Vividion Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vividion Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. IPO 25-Jun-2021 $100M 00000 Announced Generating Revenue/Not Profitable
6. Later Stage VC (Series C) 01-Feb-2021 00000 00000 00000 Completed Generating Revenue
5. Later Stage VC (Series B) 30-Apr-2019 0000 00000 00000 Completed Generating Revenue
4. Early Stage VC 05-Mar-2018 00000 00000 Completed Generating Revenue
3. Early Stage VC (Series A3) 24-Oct-2017 00.00 000.00 00000 Completed Generating Revenue
2. Early Stage VC (Series A2) 02-Feb-2017 $50M $53.5M 0000 Completed Generating Revenue
1. Early Stage VC (Series A) 11-Apr-2016 $3.5M $3.5M 000 Completed Generating Revenue
To view Vividion Therapeutics’s complete valuation and funding history, request access »

Vividion Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A-3 0,000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A-2 67,333,334 $0.001000 6% $0.6 $0.6 1x $0.6 24.17%
Series A 18,118,465 $0.001000 6% $0.25 $0.25 1x $0.25 6.5%
To view Vividion Therapeutics’s complete cap table history, request access »

Vividion Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnes
Drug Discovery
San Diego, CA
107 As of 2021
00000
00000000 00000

000000 0

lore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqui
0000000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000

00000000

consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut e
0000 000000000
San Carlos, CA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vividion Therapeutics Competitors (48)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
00000000 Venture Capital-Backed San Carlos, CA 00 00000 00000000000 00000
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
0000000 0000000000 Formerly VC-backed Brisbane, CA 000 000.00 00000000 000.00
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
You’re viewing 5 of 48 competitors. Get the full list »

Vividion Therapeutics Executive Team (18)

Name Title Board Seat Contact Info
Jeffrey Hatfield Co-Chief Executive Officer and Board Member
Robert Abraham Chief Scientific Officer
Nick Veomett Executive
Jordon Inloes Scientist
Jin-Quan Yu Ph.D Co-Founder
You’re viewing 5 of 18 executive team members. Get the full list »

Vividion Therapeutics Board Members (12)

Name Representing Role Since
Benjamin Cravatt Ph.D Vividion Therapeutics Co-Founder, Scientific Advisor & Board Member 000 0000
Catherine Friedman Self Board Member 000 0000
Christine Siu Self Board Member 000 0000
Jakob Loven Ph.D Nextech Invest Board Member 000 0000
Jeffrey Hatfield Vividion Therapeutics Co-Chief Executive Officer and Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Vividion Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vividion Therapeutics Investors (23)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Acuta Capital Partners Hedge Fund Minority 000 0000 000000 0
BlackRock Asset Manager Minority 000 0000 000000 0
Boxer Capital Venture Capital Minority 000 0000 000000 0
Citadel (Hedge Fund) Hedge Fund Minority 000 0000 000000 0
Driehaus Capital Management Corporation Minority 000 0000 000000 0
You’re viewing 5 of 23 investors. Get the full list »